Zobrazeno 1 - 10
of 242
pro vyhledávání: '"Michelle E, Melisko"'
Publikováno v:
Cancer Medicine, Vol 12, Iss 22, Pp 20906-20917 (2023)
Abstract Background Comorbidities and symptoms in metastatic breast cancer patients impact treatment decisions and influence prognosis and quality of life. The objective of this study is to examine the concordance between physician documentation and
Externí odkaz:
https://doaj.org/article/3817f554d5424960bec2e9f8d47b0a75
Autor:
Karen Lisa Smith, Carolyn Mead‐Harvey, Gina L. Mazza, Eileen H. Shinn, Elizabeth S. Frank, Michelle E. Melisko, Cyd Eaton, Yisi Liu, Jeannine M. Salamone, Teri Pollastro, Patricia A. Spears, Nicole E. Caston, Antonio C. Wolff, Gabrielle Betty Rocque
Publikováno v:
Cancer Medicine, Vol 13, Iss 5, Pp n/a-n/a (2024)
Abstract Background Breast cancer patients experienced heightened anxiety during the pandemic. Also, modifications to clinical trial activities allowing for virtual platforms, local assessments, and greater flexibility were introduced to facilitate p
Externí odkaz:
https://doaj.org/article/39e75f7a8dae4b6cbd9def0c113298bc
Autor:
Mary Kathryn Abel, Michelle E. Melisko, Hope S. Rugo, A. Jo Chien, Italia Diaz, Julia K. Levine, Ann Griffin, Joseph McGuire, Laura J. Esserman, Hala T. Borno, Rita A. Mukhtar
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-3 (2021)
Abstract Enrollment in metastatic breast cancer trials usually requires measurable lesions, but patients with invasive lobular carcinoma (ILC) tend to form diffuse disease. We found that the proportion of patients with metastatic ILC enrolled in clin
Externí odkaz:
https://doaj.org/article/5ae74b962d5a4b5e99550871185eb4e4
Autor:
Manuela Terranova-Barberio, Nela Pawlowska, Mallika Dhawan, Mark Moasser, Amy J. Chien, Michelle E. Melisko, Hope Rugo, Roshun Rahimi, Travis Deal, Adil Daud, Michael D. Rosenblum, Scott Thomas, Pamela N. Munster
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-10 (2020)
ER-positive breast cancer patients do not usually respond to immunotherapy. In this phase II clinical trial, the authors report the safety and efficacy of combining vorinostat and pembrolizumab with tamoxifen in ER-positive breast cancers and provide
Externí odkaz:
https://doaj.org/article/64f0fec706954f5c93dba4c047a3944a
Autor:
Laura A. Huppert, Zak Walker, Moming Li, Mi-Ok Kim, Jennifer Callan, Danielle Brandman, Melanie Majure, Michelle E. Melisko, Hope S. Rugo, Spencer Behr, A. Jo Chien
Publikováno v:
Breast Cancer Research and Treatment. 197:137-148
Pseudocirrhosis is a term used to describe changes in hepatic contour that mimic cirrhosis radiographically, but lack the classic pathologic features of cirrhosis. This radiographic finding is frequently found in patients with metastatic breast cance
Autor:
Nancy U Lin, Diana Lueftner, Adam M Brufsky, Sara M Tolaney, Michelle E Melisko, Frankie Ann Holmes, Ahmad Awada
Publikováno v:
Cancer Research. 82:P2-13
Background: Among patients (pts) with HER2+ early breast cancer (EBC), the CNS continues to serve as a sanctuary for distant metastases following trastuzumab-based adjuvant treatment (von Minckwitz 2017, Piccart 2020, von Minckwitz 2019). Since the i
Autor:
A. Jo Chien, Travis Deal, Chiara A. Wabl, Mark Jesus M. Magbanua, Melanie Catherine Majure, Hope S. Rugo, Jonathan R. Renslo, Michelle E. Melisko, John W. Park, Andrei Goga, Mark M. Moasser, Ozge Gumusay, Jimmy Hwang
Publikováno v:
Cancer Research. 81:PS2-19
Background: CTCs are detectable in approximately 50% of pts with metastatic breast cancer, and elevated CTC levels are an independent negative prognostic factor. CTCs have been shown to play a valuable role in predicting outcomes in pts with ABC trea
Autor:
Jane Perlmutter, Amy Wilson, W. Fraser Symmans, Denise M. Wolf, Paul Haluska, Christina Yau, Douglas Yee, Teresa Helsten, Richard Schwab, Nola M. Hylton, Laura J. van't Veer, Joan Venticinque, Angela DeMichele, Hope S. Rugo, Claudine Isaacs, Laura J. Esserman, Donald A. Berry, Michelle E. Melisko
Publikováno v:
Cancer Research. 81:PS4-08
I-SPY2 is a neoadjuvant trial evaluating experimental therapies in combination with cytotoxic chemotherapy compared to chemotherapy alone with the primary endpoint of pathologic complete response (pCR). Abundant preclinical evidence suggested the typ
Autor:
HS Han, Christina Yau, Jane Perlmutter, Amy Wilson, Heather Beckwith, Anne M. Wallace, Tara Sanft, Ashish Sanil, Erica Stringer-Reasor, Laura J. Esserman, Zahi Mitri, Donald A. Berry, Rita Nanda, Claudine Isaacs, Alexandra Thomas, Kevin Kalinsky, Hope S. Rugo, Michelle E. Melisko, A. Jo Chien, Smita Asare, W. Fraser Symmans, Judy C. Boughey, Douglas Yee, Laura J. van't Veer, Kathy S. Albain, Amy S. Clark, Julie E. Lang, Anthony D. Elias, Nola M. Hylton, Angela DeMichele, Shi Wei, Richard Schwab
Publikováno v:
Cancer Research. 81:PD1-10
Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within molecular subtypes defined by receptor status and MammaPrint (MP) risk to evaluate novel agents as neoadjuvant therapy for women with high-risk stage II/
Autor:
Denise M. Wolf, Jane Perlmutter, Judy C. Boughey, A. Jo Chien, Meredith Buxton, Gillian L. Hirst, Douglas Yee, Angela DeMichele, Andres Forero-Torres, Scott M. Berry, Erin D. Ellis, Anthony D. Elias, Julia Wulfkuhle, Michael Alvarado, Christina Yau, Stacy L. Moulder, Nola M. Hylton, Rita Nanda, Amy Wilson, Adam Asare, Debu Tripathy, Claudine Isaacs, Melissa Paoloni, Rosa I. Gallagher, Laura J. Esserman, Richard Schwab, W. Fraser Symmans, Cheryl Ewing, Laura J. van't Veer, Jeffrey B. Matthews, Teresa Helsten, Julia L. Clennell, Barbara Haley, Emanuel F. Petricoin, Katherine Steeg, Smita Asare, Ashish Sanil, Rachel L. Yung, Erin P. Crane, Erin Roesch, Hyo S. Han, Ruby Singhrao, Michelle E. Melisko, Hope S. Rugo, Kathy S. Albain, Donald A. Berry, Anne M. Wallace, Julie E. Lang, Amy S. Clark, Kathleen Kemmer, Lamorna Brown-Swigart
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Nature communications, vol 12, iss 1
Nature Communications
Nature communications, vol 12, iss 1
Nature Communications
HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence: ad